Vertex Pharmaceuticals Inc
VRTXHealthcare|Biotechnology|USA
$434.30
-4.41 (-1.01%)
DCF (FCF)
$183.42
Tangible Book
$67.54
Graham Number
$167.26
Earnings Power
$127.09
Upcoming Data Readouts (24)
May 2026
Est. completion
P1P2Type 1 Diabetes
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
NCT05791201n=7
May 2026
Est. completion
P3Sickle Cell Disease
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649n=13
May 2026
Est. completion
P3Beta-Thalassemia
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05356195n=16
Sep 2026
Est. completion
P3Type 1 Diabetes
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
NCT06832410n=10
Oct 2026
Est. completion
P3Cystic Fibrosis
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257n=822
Nov 2026
Est. completion
P1Cystic Fibrosis
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
NCT07283770n=128
Dec 2026
Est. completion
P1P2Myotonic Dystrophy Type 1 (DM1)
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
NCT06185764n=44
Dec 2026
Est. completion
P1P2Cystic Fibrosis
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741n=39
Dec 2026
Est. completion
P2Proteinuric Kidney Disease
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
NCT06794996n=45
Dec 2026
Est. completion
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572n=401
Jan 2027
Est. completion
P3Diabetic Peripheral Neuropathic Pain
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT06696443n=455
Feb 2027
Est. completion
P1Pain
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
NCT07378865n=12
Mar 2027
Est. completion
P1Cystic Fibrosis
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
NCT07437105n=128
Apr 2027
Est. completion
P3Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419n=734
Apr 2027
Est. completion
P3Cystic Fibrosis
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183n=297
May 2027
Est. completion
P3Diabetic Peripheral Neuropathic Pain
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT06628908n=1,100
Jun 2027
Est. completion
P3Beta-Thalassemia
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT05477563n=26
Jun 2027
Est. completion
P3Diabetes Mellitus, Type 1
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
NCT04786262n=52
Jul 2027
Est. completion
P2Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037n=24
Sep 2027
Est. completion
P3Cystic Fibrosis
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older
NCT06460506n=50